

## MEMORANDUM

To: All Regional Medical Laboratory, Inc. (RML) Clients

From: Regional Medical Laboratory, Inc.  
Patti Loykasek, HTL, QIHC (ASCP), Immunology Manager  
Gerald Miller, PhD, Chief of Immunology

Date: 4/7/2017

**Subject: RML is Transitioning Infectious Disease Serology to New Instrumentation**

---

RML is implementing a new platform and new methodology for infectious disease serology. We are moving this testing to a Diasorin Liaison XL instrument that utilizes a “Flash” chemiluminescence technology (CLIA) with a paramagnetic microparticle solid phase (MP). These changes result in a more sensitive assay, wider linear range, faster assay time, and more efficient workflow. Time to result will be significantly improved. Additional changes include the following:

- Results will be numeric with an alpha interpretation.
- Reference ranges will change and are listed in the table at the online link.
- CPT codes and billing are not changing.
- Specimen type is unchanged (serum).
- Some stabilities/storage are changing and are listed in the table located at the online link.

**Please note that with changing methodology and reference ranges, use caution when comparing previous results to new methodology results.**

A livewire has been sent to all interfaced clients as an aid for building tests in client computer systems.

Please see the list of impacted infectious disease serology tests located at <http://www.rmlonline.com/downloads> then select client memos at the top of the page.

Thank you very much for your continued support and patience during this transition.

If you have any questions or concerns, contact Dr. Gerald Miller 918-744-2553 or Patti Loykasek 918-744-3117.